Biotechnology industries
Genstruct, a systems biology company, has added a prominent figure to its board of directors. Michael R. Pavia, a highly experienced executive in the pharmaceutical industry, has joined the company's board with a strong track record in developing and integrating new technologies into the drug-discovery and -development process.
Pharmaceutical industry
Metabasis Therapeutics, Inc., a biopharmaceutical company focused on metabolic diseases linked to pathways in the liver, has made a significant breakthrough in liver-targeted drug delivery using its proprietary HepDirect technology. The company has published an article in The Journal of Pharmacology and Experimental Therapeutics, presenting evidence that HepDirect prodrugs can
Pharmaceutical industry
Bioject Medical Technologies, Inc. (BJCT) has partnered with Chronimed, Inc. (CHMD) to supply Biojector 2000 (B-2000) needle-free systems and related accessories. The agreement aims to distribute the products to eligible patients using Fuzeon, an AIDS drug developed by Trimeris, Inc. in collaboration with Roche. This collaboration aims to improve the
Biotechnology industries
Amgen, Inc., has provided holders of its Liquid Yield Option Notes due 2032 (Zero Coupon-Senior) the opportunity to surrender their notes for purchase at a price of $738.68 per $1,000 of principal amount. The Put Option, which expires on March 1, 2005, allows each holder to require Amgen
Biotechnology industries
Icoria, Inc. has received a U.S. patent for their methods in identifying inhibitors of asparagine synthase as antibiotics, a novel gene target for antibiotic development in a biochemical pathway by which fungi produce asparagine. This patent covers methods that potentially increase the probability of discovering fungicides that affect this
Biotechnology industries
Sinovac Biotech Ltd., a leading biotechnology company in China, has made significant strides in research and development, commercialization, and sales of human vaccines in 2004. The company gained approval for SARS vaccine clinical trials on humans in January 2004 and completed its split flu influenza vaccine clinical trials in April,
Biotechnology industries
Tina S. Nova, a distinguished biotechnology executive, has joined the board of directors at Cyntellect, Inc., a privately held biotechnology company. Nova brings to the table extensive knowledge and experience in operational development, strategic planning, and executive management. Her unique blend of scientific expertise, strategic planning, operations expertise, and fundraising
Pharmaceutical industry
Dutch biotechnology company Crucell, NV, has been accepted as a new member of the Influenza Vaccine Supply (IVS) international task force. This move is significant as it brings a new player to the table with expertise in cell-based vaccine production. The IVS was established in February 2002 to ensure adequate
Pharmaceutical industry
The U.S. Food and Drug Administration has approved Abraxane, a new class of "protein-bound particle" drugs, for the treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Abraxane is the first in this new class of
Pharmaceutical industry
Cytos Biotechnology AG, a Swiss biotechnology company, has entered into a research and commercial license option agreement with Pfizer Inc., a leading global pharmaceutical company. This partnership aims to develop immunodrugs for animal health applications, marking a significant milestone for Cytos Biotechnology in the animal health field. Under the agreement,
Pharmaceutical industry
Diabetes researchers from Hadassah-Hebrew University Hospital in Jerusalem, Israel, along with Generex consultant Dr. Pankaj Modi, have published a research paper on Oral-Lyn, a buccal insulin spray. The study, published in the December 2004 edition of Clinical Therapeutics, compared the pharmacokinetic and pharmacodynamic properties of Oral-Lyn and subcutaneous insulin in
Biotechnology industries
Amgen, a leading pharmaceutical company, has pledged an unprecedented $18 million in 2005 to support patient assistance programs for patients struggling with cancer or kidney disease. These programs, designed to ensure access to life-saving therapies, are funded by grants to independent non-profit charitable foundations. The increased funding will enable patients
